In the world of drug development, companies have a broad range of Contract Development Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) to choose from. Our customers choose us because of our unique particle engineering innovation and expertise as well as our demonstrated experience in delivering high-quality, on-time results.
Our passion is to help our customers achieve their product development and manufacturing goals - so they can help improve the lives of people around the world. Our array of services spans the drug development lifecycle, from early-stage development and pre-formulation to GMP production. With our proprietary Supercritical Precipitation technology as well as long-established drug development platforms like Spray Drying, we have the expertise and flexibility to approach customer challenges in more than one way.
Our customers, including "Top 15" pharmaceutical companies, appreciate our commitment to quality as well as our collaborative culture.
Our passion is to help our customers achieve their product development and manufacturing goals - so they can help improve the lives of people around the world. Our array of services spans the drug development lifecycle, from early-stage development and pre-formulation to GMP production. With our proprietary Supercritical Precipitation technology as well as long-established drug development platforms like Spray Drying, we have the expertise and flexibility to approach customer challenges in more than one way.
Our customers, including "Top 15" pharmaceutical companies, appreciate our commitment to quality as well as our collaborative culture.
Services
CritiTech provides our customers with a variety of platforms and supporting technologies to aid in the drug development process.
From our proprietary Supercritical Precipitation platform to both custom-developed and established Spray Drying technologies, we can provide your team with options that will best suit your needs.
From our proprietary Supercritical Precipitation platform to both custom-developed and established Spray Drying technologies, we can provide your team with options that will best suit your needs.
Can you imagine if your contract partners were as invested in your success as much as you?.
As a growing Contract Drug Manufacturing Organization (CDMO), we believe in novel approaches in both science and business.
Our seasoned technical team spent decades working in the pharmaceuticals industry and learned as much about what not to do as much as what to do.
We embrace innovation in the laboratory and approach our customer relationships as partnerships.
Ultimately, we want the same thing - for your drug development program to be as successful and impactful as possible.
As a growing Contract Drug Manufacturing Organization (CDMO), we believe in novel approaches in both science and business.
Our seasoned technical team spent decades working in the pharmaceuticals industry and learned as much about what not to do as much as what to do.
We embrace innovation in the laboratory and approach our customer relationships as partnerships.
Ultimately, we want the same thing - for your drug development program to be as successful and impactful as possible.
D., is CritiTech's Chief Scientific Officer.
He provides leadership to our scientific and technical teams regarding all areas of drug development from POC through commercial manufacturing.
He also provides hands-on assistance to our clients.
For 35 years before Dr. Baltezor joined CritiTech in 2014, he spent his career in the pharmaceutical industry where he developed deep expertise in pharmaceutical chemistry and product development, analytical chemistry, toxicology, pharmacology, formulation, drug delivery, CMC, regulatory documentation, cGMP, Phase II and commercial production, quality operations and FDA audits.
He provides leadership to our scientific and technical teams regarding all areas of drug development from POC through commercial manufacturing.
He also provides hands-on assistance to our clients.
For 35 years before Dr. Baltezor joined CritiTech in 2014, he spent his career in the pharmaceutical industry where he developed deep expertise in pharmaceutical chemistry and product development, analytical chemistry, toxicology, pharmacology, formulation, drug delivery, CMC, regulatory documentation, cGMP, Phase II and commercial production, quality operations and FDA audits.
John Reynolds is CritiTech's Director of Quality Operations.
In this role, John leads all Quality Assurance operations and oversight, including cGMP compliance, quality systems, tracking, controls and internal audit.
Before joining CritiTech in 2017, John spent over 30 years in quality operations leadership roles with Colgate-Palmolive, Marion Merrell Dow and Sanofi Aventis Pharmaceuticals.
His experience spans raw material testing, method transfers and development, validation, packaging, a variety of audits including FDA, supplier, client and DQ/IQ/OQ/PQ audits, analytical services and stability testing.
In this role, John leads all Quality Assurance operations and oversight, including cGMP compliance, quality systems, tracking, controls and internal audit.
Before joining CritiTech in 2017, John spent over 30 years in quality operations leadership roles with Colgate-Palmolive, Marion Merrell Dow and Sanofi Aventis Pharmaceuticals.
His experience spans raw material testing, method transfers and development, validation, packaging, a variety of audits including FDA, supplier, client and DQ/IQ/OQ/PQ audits, analytical services and stability testing.
Sam Campbell is CritiTech's Chairman, providing guidance to the management team.
He assists with long-term strategic development and helps with special projects.
Sam has over 30 years of experience with executive leadership and investment management with early-stage life science companies.
Prior to joining CritiTech in 2003, Sam held roles as the President of Campbell-Becker, and early stage investor for several life science companies, as well as Developer of the Lawrence Life Sciences Center, part of the largest university-based incubator in the midwest.
He assists with long-term strategic development and helps with special projects.
Sam has over 30 years of experience with executive leadership and investment management with early-stage life science companies.
Prior to joining CritiTech in 2003, Sam held roles as the President of Campbell-Becker, and early stage investor for several life science companies, as well as Developer of the Lawrence Life Sciences Center, part of the largest university-based incubator in the midwest.
Reviews
Be the first to review Crititech.
Write a Review
